Cardiff Oncology, Inc. (CRDF) vs electroCore, Inc. (ECOR)

A side-by-side comparison of Cardiff Oncology, Inc. and electroCore, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CRDF vs ECOR

growth of $100 · dividends reinvested · last 8y
CRDF -76.8% (-16.7%/yr)ECOR -96.6% (-34.5%/yr)CRDF compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002020202220242026$23$3
CRDF ECOR

CRDF vs ECOR: by the numbers

  • •ECOR is the larger company ($92M vs $87M market cap).
  • •Both run net losses; ECOR's is the smaller (-39.96% vs -7884.06% net margin).
  • •ECOR grew revenue faster over the past five years (52.51% vs 5.15% CAGR).

Metrics side by side

Valuation

MetricCRDFECOR
P/S ratio172.202.49
P/B ratio3.30N/A

Profitability

MetricCRDFECOR
Gross margin100.00%87.06%
Operating margin-8256.32%-37.64%
Net margin-7884.06%-39.96%
ROE-150.95%N/A
ROIC-159.30%-217.73%

Growth (annualized)

MetricCRDFECOR
Revenue CAGR (5Y)5.15%52.51%
Total return CAGR (5Y)-30.36%-8.10%

Frequently asked

Which has grown faster, CRDF or ECOR?
Over the past five years, ECOR grew revenue faster — CRDF at a 5.15% CAGR versus ECOR at 52.51%.
How have CRDF and ECOR total returns compared?
Over the past 5 years, CRDF delivered -30.36% and ECOR delivered -8.10% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.